ADPT
$13.47+0.15 (+1.13%)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Recent News
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Insider Sales Put Focus On Adaptive Biotechnologies Growth Story And Dilution Risk
Multiple insider sales by senior executives at Adaptive Biotechnologies (NasdaqGS:ADPT) were disclosed following the company’s strong quarterly results. The CEO and Chief Scientific Officer reported sizable share disposals executed under pre arranged 10b5-1 trading plans. These insider transactions occurred shortly after earnings that exceeded analyst expectations and during a period of increased investor interest in the company’s growth prospects. Adaptive Biotechnologies focuses on immune...
Adaptive Biotechnologies CEO Flags MRD Momentum, Lifts 2025 Volume Outlook to 30%+ at TD Cowen Conf.
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins told investors at the 46th Annual TD Cowen Healthcare Conference that the company is looking to build on what he described as strong recent performance in minimal residual disease (MRD) testing, while continuing to invest in its immune medicine
Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)?
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the best hot stocks under $20 to buy. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) received several bullish rating updates following its fiscal Q4 and full-year 2025 earnings release on February 5. On February 6, TD Cowen lifted the price target on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) to $21 from $20 while […]
TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT)
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is among the Most Volatile Stocks. On February 6, 2026, TD Cowen upgraded Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s price target to $21 from $20 while keeping a Buy rating, citing a Q4 beat and an improved outlook. TD Cowen said that community adoption, new indications, pharma guidelines, EMR integrations, and a shift […]